<p>Omentin-1, an adipokine mostly released in stromal vascular portion of adipose tissue, contributes to inflammatory disorders. It improves energy homeostasis, cardiovascular function, glucose metabolism, and reduce oxidative stress. This study aims to evaluate levels of omentin-1, atherogenic indices, and high sensitive C-reactive protein as predictors of cardiovascular diseases in women with subclinical hypothyroidism (SCHT). Fifty newly diagnosed subclinical hypothyroid females and 40 healthy females matched in age with cases, are enrolled in present study. Thyroid function tests (TSH, FT3, and FT4) and Thyroid peroxidase antibody (A-TPO) were measured using electrochemiluminescence assay. Fasting blood glucose, lipid profile, and high sensitive C-reactive protein are analyzed by photometric measuring unit. Omentin-1 is analyzed by the Enzyme Linked Immunosorbent Assay (ELISA). Omentin-1 concentrations significantly decrease among women with SCHT compared to healthy controls. Furthermore, there is a significant elevation in Atherogenic indices (AIs), total cholesterol (TC), triglyceride (TG), low- density lipoprotein-cholesterol (LDL-c), very low-density lipoprotein-cholesterol (VLDL-c), and high sensitive C-reactive protein (hsCRP) among SCHT group. Omentin-1 showed a significant positive correlation with hsCRP, while a significant negative association found between omentin-1 and TSH as well as atherogenic index of plasma (AIP). ROC curve analysis for omentin-1 revealed it as potential biomarkers to predict development and progression of cardiovascular disease (CAD). The present study concluded that women with SCHT are more at risk of CVD and that omentin-1, atherogenic indices and hsCRP are potential biomarkers to predict development and progression of CAD in patients with subclinical hypothyroidism, thus requiring timely intervention. Atherogenic indices should be assessed in patients with normal lipid profile to enhance the evaluation of atherogenic risk.</p>